Canagliflozin and cardiovascular and renal events in type 2 diabetes

Volume: 377, Issue: 7, Pages: 644 - 657
Published: Jun 12, 2017
Abstract
BackgroundCanagliflozin is a sodium–glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We report the effects of treatment with canagliflozin on cardiovascular, renal, and safety outcomes. MethodsThe CANVAS Program integrated data from two trials involving a total of 10,142 participants with type 2 diabetes and high cardiovascular risk. Participants in each...
Paper Details
Title
Canagliflozin and cardiovascular and renal events in type 2 diabetes
Published Date
Jun 12, 2017
Volume
377
Issue
7
Pages
644 - 657
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.